Your browser doesn't support javascript.
loading
Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo, Mengxin; Xu, Yongjin; Chen, Haifeng; Wu, Yiquan; Pang, Ao; Hu, Junjie; Dong, Xiaowu; Che, Jinxin; Yang, Haiyan.
Affiliation
  • Luo M; Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design,
  • Xu Y; Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China.
  • Chen H; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Wu Y; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Pang A; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • Hu J; Women's Hospital, School of Medicine Zhejiang University, Hangzhou, China.
  • Dong X; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Hangzhou, 310018, PR China; Cancer Center, Zhej
  • Che J; Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China. Electronic address: chejx@zju.edu.cn.
  • Yang H; Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, PR China. Electronic address: yanghy@zjcc.org.cn.
Eur J Med Chem ; 244: 114847, 2022 Dec 15.
Article in En | MEDLINE | ID: mdl-36265280
ABSTRACT
The Hippo pathway is an evolutionarily conserved signaling pathway that plays critical roles in the tumorigenesis and progression of breast cancer, oral cancer, rectal cancer, colloid cancer, and so on. YAP/TAZ-TEAD complex is a key knot in the Hippo pathway regulating cell proliferation and stem cell functions. Activation or overexpression of this complex has been proved to lead to cell transformation, proliferation and eventually cancerization. In this review, the association between the alterations of hippo pathway and tumorigenesis of various cancer had been elucidated. The structural basis of YAP/TAZ-TEAD complex is analyzed, and the targeting inhibitors are summarized within the medicinal chemistry classification. Moreover, we have also discussed the clinical status and current challenges of these drug candidates, and provide guidance for the future development of inhibitors targeting this pathway, especially YAP/TAZ-TEAD complex.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinogenesis / Hippo Signaling Pathway / YAP-Signaling Proteins / TEA Domain Transcription Factors / Transcriptional Coactivator with PDZ-Binding Motif Proteins / Neoplasms / Antineoplastic Agents Type of study: Guideline Limits: Humans Language: En Journal: Eur J Med Chem Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinogenesis / Hippo Signaling Pathway / YAP-Signaling Proteins / TEA Domain Transcription Factors / Transcriptional Coactivator with PDZ-Binding Motif Proteins / Neoplasms / Antineoplastic Agents Type of study: Guideline Limits: Humans Language: En Journal: Eur J Med Chem Year: 2022 Document type: Article
...